Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

Información del proyecto

CRISPR-SELECT

Identificador del acuerdo de subvención: 101158249

DOI

10.3030/101158249

Proyecto cerrado

Fecha de la firma de la CE 6 Febrero 2024

Fecha de inicio 1 Abril 2024

Fecha de finalización 30 Septiembre 2025

Financiado con arreglo a

• European Research Council (ERC)

Coste total

Sin datos

Aportación de la UE

€ 150 000,00

Coordinado por

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

Periodic Reporting for period 1 - CRISPR-SELECT (Harnessing a novel CRISPR nuclease for programmable counterselection in human cells)

Período documentado: 2024-04-01 hasta 2025-09-30

Resumen del contexto y de los objetivos generales del proyecto

CRISPR technologies and their creation of defined DNA edits in virtually any organism are revolutionizing medicine, agriculture, basic research, and biotechnology. However, editing is often inefficient, requiring additional and often laborious screening steps. My group’s recent work, which stemmed from my ERC Consolidator Award, offers a unique opportunity: achieving the first means to select for a desired gene edit in eukaryotic cells. Such a capability could relieve this pain point, becoming a highly desirable approach across many applications of genome editing. Through this project, we will achieve a proof-of-concept demonstration and lay the groundwork for commercialization and widespread adoption.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The project achieved the proof-of-principle demonstration of enriching gene edits in human cells through two modalities: indel formation and prime editing. The resulting work is currently in submission as a revised manuscript.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Further IP was secured through a variant of the Cas12a2 nucleases called Cas12a3. Future implementation will require follow-on demonstrations, development of guide rules, and expansion to other cell lines and organisms, such as plants.